With the introduction of PDL1 inhibitor drugs that offer various advances in cancer therapy, we worked with BMS, a pharmaceutical company manufacturing these drugs, to assist them in allowing hospitals to provide this treatment to their patients.  

We designed a model, representing the general class of PDL1 drugs, that illustrates the global impact in terms of number of patients treated, the specific impact of this class of drugs, and their effects on both inpatient and outpatient care. For each hospital BMS contacted, we were able to simulate the number of patients that would need treatment, the duration of these treatments, and the amount of money the hospital would need to allocate per patient, thereby informing them of the total sum of money they would need to prepare in order to provide this drug to their patients. Furthermore, the model was able to assess the impact of using the drug on both the hospital budget and within the global drug budget of the region.